Altos Labs

Pre-clinical

Cambridge, United KingdomFounded 2022altoslabs.com

Altos Labs is a well-funded, private biotechnology company with a mission to restore cell health and resilience through cellular rejuvenation, aiming to reverse a broad spectrum of diseases. Founded on the groundbreaking work of scientists like Shinya Yamanaka and Juan Carlos Izpisua Belmonte, the company has established a global presence with institutes in key biotech hubs. Its strategy combines deep biological research, a powerful computational ecosystem, and a hybrid academic-industry model to accelerate the discovery and development of novel therapeutics.

Founded

2022

Focus

Regenerative MedicineGenetics & Genomics

AI Company Overview

Technology Platform

A cellular rejuvenation programming platform based on partial reprogramming science (Yamanaka factors), aiming to transiently reset cellular age and restore health and resilience to treat and reverse a wide range of diseases.

Funding History

Total raised: $540M

Seed$270MJeff BezosJan 15, 2022

Opportunities

The opportunity lies in creating a first-in-class therapeutic modality that addresses the root cause of multiple chronic, age-related diseases.

Success could open multi-billion dollar markets in neurology, cardiology, and regenerative medicine, fundamentally shifting healthcare from management to reversal.

Risk Factors

Key risks include the unproven safety of in vivo reprogramming in humans (e.g., cancer risk), the immense challenge of translating complex biology into a drug, defining regulatory pathways for 'rejuvenation' therapies, and executing effectively under a novel and costly global research model.

Competitive Landscape

Competes with other reprogramming biotechs (Life Biosciences, Rejuvenate Bio), senolytic companies (Unity), and well-funded research entities (Calico). Differentiation stems from unparalleled funding, direct lineage to foundational science, a hybrid research model, and deep computational integration.